Compounds Australia is excited to announce a new partnership with opnMe, the open innovation portal of Boehringer Ingelheim that fosters science and collaboration initiatives in areas of high unmet medical need.
OpnMe has shared their collection of high-quality, well-characterised tool compounds with Compounds Australia to add to the facility’s existing Open Access compound collection. Through Compounds Australia, the opnMe collection can now be accessed in flexible assay-ready formats by researchers across Australia and around the world to fuel their drug discovery programs.
Watch the opnMe Collection deposited into Compounds Australia’s automated sample store below!
Dr Florian Montel, Head of Open Science at Boehringer Ingelheim said “Through partnership with Compounds Australia, who have the capability to manage and dispense large compound libraries in a wide range of assay-ready formats, we hope to make it even easier for researchers to access and use the opnMe collection.”
The opnMe collection contains over 90 molecules rigorously quality-controlled and carefully selected for relevance to key disease research topics. It covers a wide range of mechanisms of action against contemporary targets, including GPCRs, nuclear receptors, epigenetic targets, membrane transporters, ion channels, kinases, RNA targets, PROTACs, and enzymes.
Professor Sally-Ann Poulsen, Academic Director of Compounds Australia said “Compounds Australia and opnMe share a vision to facilitate drug discovery by sharing research tools and resources. With this partnership, our goal is to further accelerate drug discovery and promote information- and resource- sharing and collaborations to meet global health needs.”
#OpenInnovation #OpenScience